Loading...

Synairgen

BST:OMY
Snowflake Description

Flawless balance sheet and overvalued.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
OMY
BST
£15M
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

Synairgen plc discovers and develops drugs for respiratory diseases. The last earnings update was 54 days ago. More info.


Add to Portfolio Compare Print
  • Synairgen has significant price volatility in the past 3 months.
OMY Share Price and Events
7 Day Returns
0%
BST:OMY
-2.4%
DE Biotechs
1.8%
DE Market
1 Year Returns
6.3%
BST:OMY
-10.2%
DE Biotechs
-6%
DE Market
OMY Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Synairgen (OMY) 0% -3.6% -15.6% 6.3% - -
DE Biotechs -2.4% 1.8% -7.7% -10.2% 51.2% 10.1%
DE Market 1.8% 4.2% 7.4% -6% 10.1% 15.4%
1 Year Return vs Industry and Market
  • OMY outperformed the Biotechs industry which returned -10.2% over the past year.
  • OMY outperformed the Market in Germany which returned -6% over the past year.
Price Volatility
OMY
Industry
5yr Volatility vs Market
Related Companies

Value

 Is Synairgen undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Synairgen. This is due to cash flow or dividend data being unavailable. The share price is €0.135.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Synairgen's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Synairgen's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
BST:OMY PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in GBP £-0.03
AIM:SNG Share Price ** AIM (2019-04-18) in GBP £0.14
Europe Biotechs Industry PE Ratio Median Figure of 30 Publicly-Listed Biotechs Companies 22.44x
Germany Market PE Ratio Median Figure of 422 Publicly-Listed Companies 19.59x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Synairgen.

BST:OMY PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= AIM:SNG Share Price ÷ EPS (both in GBP)

= 0.14 ÷ -0.03

-3.9x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Synairgen is loss making, we can't compare its value to the Europe Biotechs industry average.
  • Synairgen is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does Synairgen's expected growth come at a high price?
Raw Data
BST:OMY PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -3.9x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 1 Analysts
Not available
Europe Biotechs Industry PEG Ratio Median Figure of 22 Publicly-Listed Biotechs Companies 1.3x
Germany Market PEG Ratio Median Figure of 270 Publicly-Listed Companies 1.57x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Synairgen, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Synairgen's assets?
Raw Data
BST:OMY PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in GBP £0.06
AIM:SNG Share Price * AIM (2019-04-18) in GBP £0.14
Germany Biotechs Industry PB Ratio Median Figure of 15 Publicly-Listed Biotechs Companies 3.71x
Germany Market PB Ratio Median Figure of 570 Publicly-Listed Companies 1.84x
BST:OMY PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= AIM:SNG Share Price ÷ Book Value per Share (both in GBP)

= 0.14 ÷ 0.06

2.22x

* Primary Listing of Synairgen.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Synairgen is good value based on assets compared to the DE Biotechs industry average.
X
Value checks
We assess Synairgen's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Synairgen has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Synairgen expected to perform in the next 1 to 3 years based on estimates from 1 analyst?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
47.5%
Expected Biotechs industry annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Synairgen expected to grow at an attractive rate?
  • Unable to compare Synairgen's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
  • Unable to compare Synairgen's earnings growth to the Germany market average as no estimate data is available.
  • Unable to compare Synairgen's revenue growth to the Germany market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
BST:OMY Future Growth Rates Data Sources
Data Point Source Value (per year)
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 47.5%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 26%
Germany Market Earnings Growth Rate Market Cap Weighted Average 11.5%
Germany Market Revenue Growth Rate Market Cap Weighted Average 4.8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
BST:OMY Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below
All numbers in GBP Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
BST:OMY Future Estimates Data
Date (Data in GBP Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2019-12-31 0 -5 -4 1
BST:OMY Past Financials Data
Date (Data in GBP Millions) Revenue Cash Flow Net Income *
2018-12-31 0 -4 -3
2018-09-30 3 -1 -1
2018-06-30 5 2 2
2018-03-31 5 2 2
2017-12-31 5 2 2
2017-09-30 3 -1 0
2017-06-30 0 -3 -3
2017-03-31 0 -3 -3
2016-12-31 -3 -3
2016-09-30 0 -3 -3
2016-06-30 0 -2 -3
2016-03-31 0 -2 -2

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Unable to determine if Synairgen is high growth as no earnings estimate data is available.
  • Unable to determine if Synairgen is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
BST:OMY Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below

All data from Synairgen Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

BST:OMY Future Estimates Data
Date (Data in GBP Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2019-12-31 -0.04 -0.04 -0.04 1.00
BST:OMY Past Financials Data
Date (Data in GBP Millions) EPS *
2018-12-31 -0.03
2018-09-30 -0.01
2018-06-30 0.02
2018-03-31 0.02
2017-12-31 0.02
2017-09-30 -0.01
2017-06-30 -0.03
2017-03-31 -0.03
2016-12-31 -0.03
2016-09-30 -0.03
2016-06-30 -0.03
2016-03-31 -0.03

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Synairgen will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess Synairgen's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Synairgen has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Synairgen performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Synairgen's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Synairgen does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Synairgen's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Synairgen's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Synairgen's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Synairgen Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

BST:OMY Past Revenue, Cash Flow and Net Income Data
Date (Data in GBP Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 0.11 -3.30 1.01 3.23
2018-09-30 2.57 -0.90 1.18 2.79
2018-06-30 5.03 1.50 1.35 2.35
2018-03-31 5.03 1.63 1.35 2.21
2017-12-31 5.03 1.76 1.35 2.06
2017-09-30 2.53 -0.47 1.17 2.21
2017-06-30 0.03 -2.70 1.00 2.36
2017-03-31 0.01 -2.76 1.01 2.39
2016-12-31 -2.82 1.02 2.42
2016-09-30 0.00 -2.77 1.12 2.23
2016-06-30 0.00 -2.73 1.22 2.03
2016-03-31 0.01 -2.49 1.25 1.69
2015-12-31 0.03 -2.26 1.28 1.36
2015-09-30 0.05 -1.94 1.16 1.11
2015-06-30 0.07 -1.62 1.04 0.86
2015-03-31 2.18 -0.22 1.29 1.25
2014-12-31 4.29 1.19 1.55 1.65
2014-09-30 4.27 1.05 1.56 1.76
2014-06-30 4.25 0.92 1.57 1.88
2014-03-31 2.13 -0.56 1.28 1.58
2013-12-31 -2.04 0.99 1.29
2013-09-30 -2.10 0.98 1.37
2013-06-30 -2.16 0.97 1.44
2013-03-31 -2.21 0.98 1.48
2012-12-31 -2.25 0.98 1.51
2012-06-30 0.00 -3.12 0.95 2.56

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Synairgen has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Synairgen has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Synairgen improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Synairgen's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Synairgen has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Synairgen's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Synairgen's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Synairgen is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Synairgen has no long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Synairgen's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Synairgen has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Synairgen Company Filings, last reported 3 months ago.

BST:OMY Past Debt and Equity Data
Date (Data in GBP Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 6.03 0.00 5.33
2018-09-30 6.03 0.00 5.33
2018-06-30 5.09 0.00 5.31
2018-03-31 5.09 0.00 5.31
2017-12-31 6.56 0.00 6.85
2017-09-30 6.56 0.00 6.85
2017-06-30 3.48 0.00 3.08
2017-03-31 3.48 0.00 3.08
2016-12-31 4.69 0.00 4.77
2016-09-30 4.69 0.00 4.77
2016-06-30 6.05 0.00 6.31
2016-03-31 6.05 0.00 6.31
2015-12-31 7.35 0.00 7.71
2015-09-30 7.35 0.00 7.71
2015-06-30 8.60 0.00 8.73
2015-03-31 8.60 0.00 8.73
2014-12-31 9.44 0.00 9.60
2014-09-30 9.44 0.00 9.60
2014-06-30 4.98 0.00 6.08
2014-03-31 4.98 0.00 6.08
2013-12-31 1.58 0.00 1.29
2013-09-30 1.58 0.00 1.29
2013-06-30 2.46 0.00 2.14
2013-03-31 2.46 0.00 2.14
2012-12-31 3.42 0.00 3.09
2012-06-30 2.07 0.00 2.25
  • Synairgen has no debt.
  • Synairgen has not taken on any debt in the past 5 years.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Synairgen has sufficient cash runway for 1.3 years based on current free cash flow.
  • Synairgen has sufficient cash runway for 1.4 years if free cash flow continues to reduce at historical rates of -35.4% each year.
X
Financial health checks
We assess Synairgen's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Synairgen has a total score of 6/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Synairgen's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Synairgen dividends.
If you bought €2,000 of Synairgen shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Synairgen's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Synairgen's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
BST:OMY Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 0.9%
Germany Market Average Dividend Yield Market Cap Weighted Average of 326 Stocks 3%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.8%
Germany Bottom 25% Dividend Yield 25th Percentile 1.4%
Germany Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

BST:OMY Future Dividends Estimate Data
Date (Data in £) Dividend per Share (annual) Avg. No. Analysts
2019-12-31

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Synairgen has not reported any payouts.
  • Unable to verify if Synairgen's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Synairgen's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Synairgen has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Synairgen's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Synairgen afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Synairgen has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Synairgen's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Richard Marsden
COMPENSATION £336,000
AGE 50
TENURE AS CEO 9.6 years
CEO Bio

Mr. Richard Marsden has been Chief Executive Officer of Synairgen Research Ltd since September 2009. Mr. Marsden has been Managing Director and Executive Director at Synairgen since June 2004 has been its Chief Executive Officer since September 2009. Mr. Marsden joined Synairgen in a consulting role as General Manager in November 2003. From 1998 to 2003, he worked as Projects Manager and Cystic Fibrosis Business Development Manager at Profile Therapeutics plc, where he managed the Cystic Fibrosis business and played a major role in the development of its proprietary pharmaceutical unit, Profile Pharma Limited. Prior to this, he worked for Zimmer Limited, Genentech (UK) Limited and Roche Products Limited. He serves as a Director of Synairgen Research Ltd.

CEO Compensation
  • Richard's compensation has increased whilst company is loss making.
  • Richard's remuneration is higher than average for companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the Synairgen management team in years:

9.6
Average Tenure
50
Average Age
  • The average tenure for the Synairgen management team is over 5 years, this suggests they are a seasoned and experienced team.
Management Team

Richard Marsden

TITLE
Chief Executive Officer
COMPENSATION
£336K
AGE
50
TENURE
9.6 yrs

John Ward

TITLE
Finance Director
COMPENSATION
£263K
AGE
56
TENURE
14.5 yrs

Phillip Monk

TITLE
Chairman of Scientific Advisory Board
COMPENSATION
£241K
AGE
49
TENURE
9.6 yrs

Donna Davies

TITLE
Co-Founder & Member of Scientific Advisory Board

Ratko Djukanovic

TITLE
Co-Founder & Member of Scientific Advisory Board
Board of Directors Tenure

Average tenure and age of the Synairgen board of directors in years:

14.7
Average Tenure
57
Average Age
  • The average tenure for the Synairgen board of directors is over 10 years, this suggests they are a seasoned and experienced board.
Board of Directors

Simon James Shaw

TITLE
Non-Executive Chairman
COMPENSATION
£30K
AGE
53
TENURE
15.8 yrs

Richard Marsden

TITLE
Chief Executive Officer
COMPENSATION
£336K
AGE
50
TENURE
14.8 yrs

John Ward

TITLE
Finance Director
COMPENSATION
£263K
AGE
56
TENURE
14.5 yrs

Phillip Monk

TITLE
Chairman of Scientific Advisory Board
COMPENSATION
£241K
AGE
49

Donna Davies

TITLE
Co-Founder & Member of Scientific Advisory Board

Ratko Djukanovic

TITLE
Co-Founder & Member of Scientific Advisory Board

Paul Hugh Clegg

TITLE
Non-Executive Director
COMPENSATION
£30K
AGE
58
TENURE
9.6 yrs

Stephen Holgate

TITLE
Co-Founder
COMPENSATION
£25K
AGE
70
TENURE
15.8 yrs

David Campbell

TITLE
Non-Executive Director & Member of Scientific Advisory Board
COMPENSATION
£25K
AGE
73

Iain Peter Buchanan

TITLE
Non-Executive Director & Member of Scientific Advisory Board
COMPENSATION
£25K
AGE
64
TENURE
8.8 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
X
Management checks
We assess Synairgen's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Synairgen has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Description

Synairgen plc discovers and develops drugs for respiratory diseases. It develops inhaled interferon beta (IFN-ß), which is in Phase-II clinical trials for the treatment or prevention of asthma exacerbations caused by the common cold; IFN-ß that is in Phase-I clinical trial for the treatment or prevention of chronic obstructive pulmonary disease exacerbations caused by the common cold; and LOXL2 inhibitor, which is in Phase I clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF). Synairgen plc has research collaboration with Pharmaxis Ltd. to develop a LOXL2 inhibitor to the lysyl oxidase type 2 enzyme to treat IPF, a lung disease. Synairgen plc was incorporated in 2004 and is headquartered in Southampton, the United Kingdom.

Details
Name: Synairgen plc
OMY
Exchange: BST
Founded: 2004
£17,077,164
109,433,442
Website: http://www.synairgen.com
Address: Synairgen plc
Mailpoint 810,
Level F, South Block,
Southampton,
Hampshire, SO16 6YD,
United Kingdom
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
AIM SNG Ordinary Shares London Stock Exchange AIM Market GB GBP 26. Oct 2004
BST OMY Ordinary Shares Boerse-Stuttgart DE EUR 26. Oct 2004
Number of employees
Current staff
Staff numbers
11
Synairgen employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/04/20 21:59
End of day share price update: 2019/04/18 00:00
Last estimates confirmation: 2019/02/25
Last earnings filing: 2019/02/25
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.